Business Context and Reporting Period
Rigetti Computing, Inc. filed a Form 8-K reporting management changes and related executive compensation arrangements. The report date was December 7, 2022, and the filing was signed on December 8, 2022. The company is an emerging growth company whose common stock and warrants trade on Nasdaq under RGTI and RGTIW.
Key Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics.
- Dr. Subodh Kulkarni was appointed President and Chief Executive Officer effective December 12, 2022.
- Annual base salary: $585,000, prorated initially while Dr. Kulkarni completes transition consulting for CyberOptics through January 8, 2023.
- Target discretionary annual cash bonus beginning in 2023: $290,000.
- Potential relocation benefit: $130,000 if he relocates to the Bay Area within 120 days of the effective date.
- Initial stock option: up to 1,250,000 shares, with an exercise price equal to the closing stock price on the grant date and generally monthly vesting after an initial one-year vesting period.
- Performance options: up to 500,000 shares, with 250,000 shares tied to a $5.00 stock-price threshold and 250,000 shares tied to a $10.00 threshold, each requiring the threshold to be met for 20 trading days during a consecutive 30-trading-day period within five years.
Material Changes Versus the Prior Period
- Rick Danis will step down as Interim President and Chief Executive Officer on December 12, 2022, and will continue as General Counsel and Corporate Secretary.
- Dr. Chad Rigetti was expected to depart the Board of Directors on December 15, 2022.
- Dr. Kulkarni was expected to join the Board following Dr. Rigetti’s departure.
- The company entered into a new executive employment agreement with Dr. Kulkarni dated December 7, 2022.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing provides no revenue or earnings guidance.
- Dr. Kulkarni’s employment is at will. The agreement includes severance provisions if the company terminates him without cause or he resigns for good reason.
- Non-change-in-control severance may include 24 months of base salary, 24 months of COBRA premiums, a bonus equal to twice the target bonus, and acceleration of time-based equity vesting.
- Specified change-in-control severance may include twice his then-current annual salary, 24 months of COBRA premiums, a bonus equal to twice the target bonus, and acceleration of time-based equity vesting.
- Performance options may be forfeited if the applicable stock-price requirements are not met by the fifth anniversary of the effective date.
- The initial 50% work commitment through January 8, 2023 reflects Dr. Kulkarni’s transition consulting obligations to CyberOptics.
- The filing does not state the grant dates, final exercise prices, fair values, or expected accounting expense for the equity awards.
Important Facts for Investors to Verify
- Confirm the final grant dates, exercise prices, vesting terms, and accounting valuation of the 1,750,000 potential option shares.
- Review the complete executive employment agreement filed as Exhibit 10.1 for definitions, termination conditions, and severance limitations.
- Verify whether Dr. Kulkarni joined the Board and whether the expected leadership transition occurred as described.
- Assess the potential dilution and future compensation expense from the equity awards.
- Review subsequent filings for changes in management, liquidity, operating performance, and execution of the company’s business plan.